GLP-1s, a class of drugs used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have exploded in popularity in recent years due to their demonstrated effectiveness, but are often not covered by insurance, particularly for the treatment of obesity
The evolving framework under ICH S1B(R1) further emphasizes a modern, evidence-integrated approach to long-term safety evaluation
I self inject NHS prescription that's what the pharmacy I.T cant cope with
discontinue if weight loss is less than 5% Regular weight measurements and BMI calculations Monitoring for adverse effects, particularly gastrointestinal symptoms Blood pressure and cardiovascular risk factor assessment Periodic blood tests to monitor metabolic parameters For patients with diabetes who are taking insulin or sulfonylureas, doses of these medications may need to be reduced when starting GLP-1 receptor agonists to prevent hypoglycaemia
Why a Medical Weight Loss Doctor Matters A prescription-only approach may focus on access to medication
